Title Physician

Outcomes of Cutaneous Melanoma Patients Clinically Tested with DecisionDx®-Melanoma: A Prospective Registry (CONNECTION PRO)

NCT ID : N/A
Protocol Number : JWC_CBI_2021_COCM_PRO
Phase : N/A
Location : Santa Monica, Ca
Richard Essner, M.D.

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT ID : 05155254
Protocol Number : IO102-IO103-013
Phase : III
Location : Santa Monica, Ca
Kim Margolin, M.D.

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)

NCT ID : 04382664
Protocol Number : JWC_UV1-202
Phase : II
Location : Santa Monica, Ca
Kim Margolin, M.D.

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Melanoma (MORPHEUS-MELANOMA)

NCT ID : 05116202
Protocol Number : JWC_BO43328_Roche
Phase : I/II
Location : Santa Monica, Ca
Kim Margolin, M.D.

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA
Richard Essner, M.D.

A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

NCT ID : 03978611
Protocol Number : CA224-083
Phase : 1/2
Location : Santa Monica, CA
Timothy Kristedja, M.D.

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

NCT ID : 04526899
Protocol Number : BNT111-01
Phase : 2
Location : Santa Monica, CA
Kim Margolin, M.D.

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)

NCT ID : 04303169
Protocol Number : MK-3475-02C
Phase : 3
Location : Santa Monica, CA
Timothy Kristedja, M.D.

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)

NCT ID : 04305054
Protocol Number : MK-3475-02B
Phase : 3
Location : Santa Monica, CA
Przemyslaw Twardowski, M.D.

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

NCT ID : 04382664
Protocol Number : UV1-202
Phase : 2
Location : Santa Monica, CA
Przemyslaw Twardowski, M.D.